Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2456274 | 1.00 | LMNA (0.31) | LMNAMAPTHTT | |
| SCHEMBL2309048 | 1.00 | LMNA (0.31) | LMNAMAPTHTT | |
| Hydrochloric Acid SCHEMBL31094833 | 0.98 | LMNA (0.33) | LMNAMAPT | |
| Trifluoroacetic Acid SCHEMBL28724275 | 0.84 | PKM (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL28058829 | 0.84 | PKM (0.35) | — | |
| SCHEMBL28301594 | 0.78 | — | — | |
| SCHEMBL21214402 | 0.78 | — | — | |
| SCHEMBL27862771 | 0.78 | — | — | |
| SCHEMBL28019741 | 0.78 | PRKD3 (0.32) | LMNAHTT | |
| SCHEMBL24429485 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230046126-A1 | ALKYNYLPHENYLBENZAMIDE COMPOUNDS AND APPLICATIONS THEREOF | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| US-20220220069-A1 | COMPOUND USED AS SIRT6 SMALL-MOLECULE ALLOSTERIC ACTIVATOR AND PHARMACEUTICAL COMPOSITION THEREOF | SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-2785710-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | ChemoCentryx, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2773639-A1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013082429-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013067277-A1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-2350075-A1 | SUBSTITUTED IMIDAZOÝ1,2B¨PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011030139-A1 | 4- (PYRIMIDIN-2-YL) -PIPERAZINE AND 4- (PYRIMIDIN-2-YL) -PIPERIDINE DERIVATIVES AS GPR119 MODULATORS | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | WO | disclosed |
| EP-2231601-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010033941-A1 | SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009075857-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220069-A1 | COMPOUND USED AS SIRT6 SMALL-MOLECULE ALLOSTERIC ACTIVATOR AND PHARMACEUTICAL COMPOSITION THEREOF | SIRT6, SIRT1, SIRT7 | LMNA 4380/4885MAPT 1263/4885HTT 1399/4885 |
| US-20230046126-A1 | ALKYNYLPHENYLBENZAMIDE COMPOUNDS AND APPLICATIONS THEREOF | ALK, NTRK1, ERBB2 | LMNA 2570/4885MAPT 4052/4885HTT 4461/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | LMNA 2363/4885MAPT 1542/4885HTT 1361/4885 |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | LMNA 3720/4885MAPT 4648/4885HTT 2990/4885 |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | ALK, NTRK1, ERBB2 | LMNA 2570/4885MAPT 4052/4885HTT 4461/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | LMNA 3525/4885MAPT 2866/4885HTT 3206/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | LMNA 3767/4885MAPT 4801/4885HTT 2692/4885 |
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | SLC10A1, CYP7A1, FABP1 | LMNA 1618/4885MAPT 2558/4885HTT 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.